RMRick van Minkelen

Rick van Minkelen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rick van Minkelen has a total of 280 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plexiform neurofibromas and malignant peripheral nerve sheath tumors in adults with neurofibromatosis type 1: Clinical insights from a large cohort

    by Daniëlle Christine Noordhoek, Lara Orlandini, Rianne Oostenbrink, Rick van Minkelen, Sarah A van Dijk, Axel Taal, Castor Taal, Walter Taal

    Background: Plexiform neurofibromas (PNs) and malignant peripheral nerve sheath tumors (MPNSTs) are major complications in adults with neurofibromatosis type 1; we analyzed their clinical features and management in a large cohort of 1,067 adults. Methods: Clinical data from all adults seen at the Dutch NF1 expertise center (2004-2025) were retrospectively collected, including NF1 diagnostic features, genetic data and details on PNs and MPNSTs. Detailed information was recorded on up to 3 largest or most symptomatic PNs per patient. Five-year survival after MPNST and risk factors for MPNST were analyzed. Known genotype-phenotype associations were evaluated. Results: Among 1,067 adult patients with NF1 (1,019 generalized, 48 mosaic), PNs were present in 47%. Surgical management was frequently limited by regrowth and complications. Overall, 5% of patients were deceased; the median age of death was 48 years, most commonly due to MPNST. MPNST occurred in 4% of the patients, predominantly in proximal body regions. The presence of nodular PNs was an independent risk factor for MPNST. Five-year survival after MPNST was 54.5%. 17q11.2 microdeletion was associated with a higher risk for MPNST. Conclusions: This large cohort study highlights that PNs and the associated risk of malignant transformation represent a significant burden for individuals with NF1. The limitations of surgical management of PNs underscore the need for effective systemic therapies. The prognosis for MPNST remains poor. Regular follow-up is essential for all patients with NF1, particularly those in high-risk subgroups.

  • Open Access

    The Relation Between Genotype and Behavioral Phenotype in Children and Adolescents With Neurofibromatosis Type 1

    by Myrthe J. Ottenhoff, Andre B. Rietman, Daniela Gawehns, Mark Nellist, Shruti Garg, Julieta O’FLaherty, Susan J. Kimber, Emma M.M. Burkitt Wright, Caroline Denayer, Ellen Denayer, et al.

  • Open Access

    Identification of the Determinants of Plexiform Neurofibroma Morbidity in Pediatric and Young Adult Neurofibromatosis Type 1 Patients: A Pilot Multivariate Approach

    by Biagio de Brons, Britt Dhaenens, Rick van Minkelen, Rianne Oostenbrink

    Background: Plexiform neurofibromas (PNs) are histologically benign peripheral nerve sheath tumors associated with neurofibromatosis type 1 (NF1) and often lead to significant morbidity due to growth. Management includes watchful waiting, surgery for partial debulking, and, since recently, systemic treatment with MEK inhibitors. However, due to the scarcity of natural history studies, our understanding of the natural progression of PNs to guide clinicians in deciding in whom and when to intervene is scarce. This study aims to describe the characteristics of NF1 patients with PNs and compare those at high risk for PN progression or experiencing significant morbidity from PN (complex PN) with NF1 patients with PNs of lower complexity. Methods: In this retrospective cohort study using clinical data from hospital records of NF1 patients with PNs seen at the Sophia Children’s Hospital in the Netherlands between 2012 and 2023, we assessed determinants of clinical phenotypes and PN characteristics predictive of outcomes, including PN complexity and the timing of intervention for PN. We assessed the outcomes using logistic regression analysis and Cox regression. Results: Ninety patients with a median age at last evaluation of 15.7 years and a median follow-up duration of 9.8 years were included. Out of 90 individuals with a benign PN, 37 developed plexiform neurofibroma morbidity during follow-up. Older age was (corrected for pathogenic NF1 variant and PN location) significantly associated with plexiform neurofibroma morbidity. Cox regression revealed that craniofacial and trunk PNs were associated with a higher intervention hazard compared to limb PNs. Conclusion: Our pilot multivariate approach identified older age and the location of the PN to be mostly associated with a higher chance of plexiform neurofibroma morbidity and higher intervention hazard. This may contribute to decisions regarding in whom and when to initiate treatment in NF1 patients with PNs.


  • Open Access

    Two novel variants in GRN: the relevance of CNV analysis and genetic screening in FTLD patients with a negative family history

    by Julie F. H. De Houwer, Elise G. P. Dopper, Ana Rajicic, Renee van Buuren, Marina Arcaro, Daniela Galimberti, Guido J. Breedveld, Martina Wilke, Rick van Minkelen, Lize C. Jiskoot, et al.

    Background Frontotemporal lobar degeneration (FTLD) is one of the leading causes of early onset dementia. Pathogenic variants in GRN have been reported to cause 5–25% of familial and 5% of sporadic FTLD. Here, we present two novel, likely pathogenic variants in GRN. Methods Four patients from four different families underwent whole exome sequencing (WES) with additional copy-number variance (CNV) analysis in a clinical setting. TMEM106B rs1990622 and rs3173615 SNPs and 3’UTR insertion were tested in one presymptomatic carrier. In three probands and one presymptomatic carrier, plasma progranulin (PGRN) levels were measured using a specific ELISA kit. In two probands, neuropathological diagnosis was established using current neuropathological criteria. Results Through CNV analysis on WES data, we identified a partial deletion, NM_002087.2 (GRN):c.1179 + 104_1536delinsCTGA, p.(?), in three patients with primary progressive aphasia and/or corticobasal syndrome. Haplotype analysis revealed a shared haplotype block, suggesting that the deletion represents a founder mutation. Additionally, we found a novel, missense variant, NM_002087.2 (GRN):c.23 T > A, p.(Val8Glu), in one proband with a negative family history. The proband’s unaffected parent—in their 80 s—carried the same variant, yet was homozygous for the TMEM106B risk haplotype. The pathogenicity of both GRN variants was supported by typical neuropathological features and reduced PGRN levels. Conclusion We recommend a thorough genetic screening, including CNV analysis, for both familial and apparent sporadic FTLD patients. Furthermore, the presymptomatic carrier homozygous for the TMEM106B risk haplotype exemplifies the presence of other protective factors that modify disease onset and urges caution in genetic counselling based on the TMEM106B haplotype.


  • Open Access

    AMFR dysfunction causes autosomal recessive spastic paraplegia in human that is amenable to statin treatment in a preclinical model

    by Ruizhi Deng, Eva Medico-Salsench, Anita Nikoncuk, Reshmi Ramakrishnan, Kristina Lanko, Nikolas A. Kühn, Herma C. van der Linde, Sarah Lor-Zade, Fatimah Albuainain, Yuwei Shi, et al.

    Hereditary spastic paraplegias (HSP) are rare, inherited neurodegenerative or neurodevelopmental disorders that mainly present with lower limb spasticity and muscle weakness due to motor neuron dysfunction. Whole genome sequencing identified bi-allelic truncating variants in AMFR, encoding a RING-H2 finger E3 ubiquitin ligase anchored at the membrane of the endoplasmic reticulum (ER), in two previously genetically unexplained HSP-affected siblings. Subsequently, international collaboration recognized additional HSP-affected individuals with similar bi-allelic truncating AMFR variants, resulting in a cohort of 20 individuals from 8 unrelated, consanguineous families. Variants segregated with a phenotype of mainly pure but also complex HSP consisting of global developmental delay, mild intellectual disability, motor dysfunction, and progressive spasticity. Patient-derived fibroblasts, neural stem cells (NSCs), and in vivo zebrafish modeling were used to investigate pathomechanisms, including initial preclinical therapy assessment. The absence of AMFR disturbs lipid homeostasis, causing lipid droplet accumulation in NSCs and patient-derived fibroblasts which is rescued upon AMFR re-expression. Electron microscopy indicates ER morphology alterations in the absence of AMFR. Similar findings are seen in amfra-/- zebrafish larvae, in addition to altered touch-evoked escape response and defects in motor neuron branching, phenocopying the HSP observed in patients. Interestingly, administration of FDA-approved statins improves touch-evoked escape response and motor neuron branching defects in amfra-/- zebrafish larvae, suggesting potential therapeutic implications. Our genetic and functional studies identify bi-allelic truncating variants in AMFR as a cause of a novel autosomal recessive HSP by altering lipid metabolism, which may potentially be therapeutically modulated using precision medicine with statins.


  • Open Access

    The Benson Complex Figure Test detects deficits in visuoconstruction and visual memory in symptomatic familial frontotemporal dementia: A GENFI study

    by Lize C. Jiskoot, Lucy L. Russell, Georgia Peakman, Rhian S. Convery, Caroline V. Greaves, Martina Bocchetta, Jackie M. Poos, Harro Seelaar, Lucia A.A. Giannini, John C. van Swieten, et al.


  • Open Access

    Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome

    by Hannie Douben, Marianne Hoogeveen-Westerveld, Mark Nellist, Jesse Louwen, Marian Kroos-De Haan, Mattijs Punt, Babeth van Ommeren, Leontine van Unen, Peter Elfferich, Esmee Kasteleijn, et al.

    Neurofibromatosis type 1 (NF1) and Legius syndrome (LS) are caused by inactivating variants in NF1 and SPRED1. NF1 encodes neurofibromin (NF), a GTPase-activating protein (GAP) for RAS that interacts with the SPRED1 product, Sprouty-related protein with an EVH (Ena/Vasp homology) domain 1 (SPRED1). Obtaining a clinical and molecular diagnosis of NF1 or LS can be challenging due to the phenotypic diversity, the size and complexity of the NF1 and SPRED1 loci, and uncertainty over the effects of some NF1 and SPRED1 variants on pre-mRNA splicing and/or protein expression and function. To improve NF1 and SPRED1 variant classification and establish pathogenicity for NF1 and SPRED1 variants identified in individuals with NF1 or LS, we analyzed patient RNA by RT-PCR and performed in vitro exon trap experiments and estimated NF and SPRED1 protein expression, RAS GAP activity, and interaction. We obtained evidence to support pathogenicity according to American College of Medical Genetics guidelines for 73/114 variants tested, demonstrating the utility of functional approaches for NF1 and SPRED1 variant classification and NF and LS diagnostics.


  • Deciphering the natural history of SCA7 in children

    by M. G. Bah, D. Rodriguez, C. Cazeneuve, F. Mochel, D. Devos, A. Suppiej, A. Roubertie, I. Meunier, C. Gitiaux, A. Curie, et al.

    Background and purpose: Childhood‐onset autosomal dominant cerebellar ataxia type 7 (SCA7) is a severe disease which leads to premature loss of ambulation and death. Early diagnosis of SCA7 is of major importance for genetic counselling and still relies on specific genetic testing, driven by clinical expertise. However, the precise phenotype and natural history of paediatric SCA7 has not yet been fully described. Our aims were to describe the natural history of SCA7 in a large multicentric series of children of all ages, and to find correlates to variables defining this natural history.Methods: We collected and analysed clinical data from 28 children with proven SCA7. All had clinical manifestations of SCA7 and either a definite number of CAG repeats in ATXN7 or a long expansion > 100 CAG.Results: We identified four clinical presentation patterns related to age at onset. Children of all age groups had cerebellar atrophy and retinal dystrophy. Our data, combined with those in the literature, suggest that definite ranges of CAG repeats determine paediatric SCA7 subtypes. The number of CAG repeats inversely correlated to all variables of the natural history. Age at gait ataxia onset correlated accurately to age at loss of walking ability and to age at death.Conclusion: SCA7 in children has four presentation patterns that are roughly correlated to the number of CAG repeats. Our depiction of the natural history of SCA7 in children may help in monitoring the effect of future therapeutic trials.


  • Open Access

    Longitudinal cognitive biomarkers predicting symptom onset in presymptomatic frontotemporal dementia

    by Lize C. Jiskoot, Jessica L. Panman, Lauren van Asseldonk, Sanne Franzen, Lieke H. H. Meeter, Laura Donker Kaat, Emma L. van der Ende, Elise G. P. Dopper, Reinier Timman, Rick van Minkelen, et al.

    Introduction We performed 4-year follow-up neuropsychological assessment to investigate cognitive decline and the prognostic abilities from presymptomatic to symptomatic familial frontotemporal dementia (FTD). Methods Presymptomatic MAPT (n = 15) and GRN mutation carriers (n = 31), and healthy controls (n = 39) underwent neuropsychological assessment every 2 years. Eight mutation carriers (5 MAPT, 3 GRN) became symptomatic. We investigated cognitive decline with multilevel regression modeling; the prognostic performance was assessed with ROC analyses and stepwise logistic regression. Results MAPT converters declined on language, attention, executive function, social cognition, and memory, and GRN converters declined on attention and executive function (p < 0.05). Cognitive decline in ScreeLing phonology (p = 0.046) and letter fluency (p = 0.046) were predictive for conversion to non-fluent variant PPA, and decline on categorical fluency (p = 0.025) for an underlying MAPT mutation. Discussion Using longitudinal neuropsychological assessment, we detected a mutation-specific pattern of cognitive decline, potentially suggesting prognostic value of neuropsychological trajectories in conversion to symptomatic FTD.


  • Open Access

    White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort

    by Carole H. Sudre, Martina Bocchetta, David Cash, David L. Thomas, Ione Woollacott, Katrina M. Dick, John van Swieten, Barbara Borroni, Daniela Galimberti, Mario Masellis, et al.